Baumgart A, Denz C, Bender H, Bauer M, Hunziker S, Schüpfer G, Schleppers A
Klinik für Anästhesiologie und Operative Intensivmedizin, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Deutschland.
Anaesthesist. 2009 Feb;58(2):180-6. doi: 10.1007/s00101-008-1483-y.
The introduction of innovative drugs in anesthesiological treatment has the potential to improve perioperative efficiency. This article examines the impact of the new muscle relaxant encapsulator Bridion on emergence from anesthesia and on the efficiency of the perioperative organization.
To analyze the effects of medical innovations, computer simulation was used as an experimental frame. The simulation was based on a realistic model of an operating room setting and used historical data to study the effect of innovation on the operational performance and the economic outcomes.
The use of medical innovations in anesthesiological emergence yields new potentials for a hospital under certain conditions. Due to shorter block times and anesthesia-controlled times, additional benefits for the operating room could be realized. This results in an increase of up to 2.4% additional cases during similar working hours and planning periods.
The introduction of innovative medicines may reveal more efficient and economical conditions in operating rooms. The overall result depends, for example, on the rate of application of the patient's portfolio or the organization and access rules of the surgical suite. Based on the anesthesia-controlled time no general a priori statement about the economic potentials can be confirmed. Future empirical studies should investigate the impact on quality and economic benefits for the entire patient pathway.
在麻醉治疗中引入创新药物有可能提高围手术期效率。本文探讨新型肌肉松弛剂布瑞亭（Bridion）对麻醉苏醒及围手术期组织效率的影响。
为分析医学创新的效果，采用计算机模拟作为实验框架。该模拟基于手术室设置的真实模型，并利用历史数据研究创新对运营绩效和经济结果的影响。
在某些条件下，麻醉苏醒中使用医学创新为医院带来了新的潜力。由于阻滞时间和麻醉控制时间缩短，手术室可实现额外收益。这导致在相似工作时间和规划期内病例数最多可增加2.4%。
创新药物的引入可能会在手术室中展现出更高效和经济的状况。总体结果例如取决于患者组合的应用率或手术套房的组织及准入规则。基于麻醉控制时间，无法确认关于经济潜力的一般性先验陈述。未来的实证研究应调查对整个患者路径的质量和经济效益的影响。
